Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 253 matching trials from the live ClinicalTrials.gov search.
Conditions
Idiopathic Parkinson's Disease, Parkinson's Disease, Basal Ganglia Disease, Brain Diseases, Central Nervous System Diseases, Movement Disorders, Nervous System Diseases, Neurodegenerative Diseases, Parkinsonian Disorders
Interventions
VY-AADC01
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
San Francisco, California • Atlanta, Georgia • Columbus, Ohio + 1 more
Conditions
Macula; Degeneration, Retina
Interventions
carbidopa-levodopa 25-100 mg
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders
Interventions
AFQ056, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Sunnyvale, California • Englewood, Colorado
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301, Observational cohort
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Scottsdale, Arizona • Fountain Valley, California • Panorama City, California + 10 more
Conditions
Parkinson Disease
Interventions
Tavapadon, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years to 80 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
54
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration

NCT01064739
Conditions
Healthy Participants
Interventions
Fava beans, Fixed Sodium Diet
Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Glioblastoma, Malignant Glioma
Interventions
Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Procedure · Other · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Conditions
Parkinson's Disease
Interventions
Kinesia HomeView, Hand-written diary
Device · Other
Lead sponsor
Great Lakes NeuroTechnologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Valley View, Ohio
Conditions
Depression
Interventions
Levodopa+carbidopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Stroke
Interventions
Telerehabilitation, Sinemet Pill, Placebo
Device · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Parkinson Disease
Interventions
Ropinirole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
28
States / cities
Birmingham, Alabama • Northridge, California • San Francisco, California + 24 more
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Interventions
Dipraglurant, Placebo
Drug
Lead sponsor
Addex Pharma S.A.
Industry
Eligibility
30 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
41
States / cities
Phoenix, Arizona • Fresno, California • Irvine, California + 38 more
Active, not recruiting Phase 3 Interventional

Infusion of Apomorphine: Long-term Safety Study

NCT02339064
Conditions
Idiopathic Parkinson's Disease
Interventions
apomorphine infusion
Drug
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more
Completed Phase 4 Interventional Results available

Effect of L-dopa In Subacute Back Pain Population

NCT01951105
Conditions
Sub-acute Back Pain
Interventions
Naproxen, Carbidopa/Levodopa, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders, Anti-Dyskinesia Agents
Interventions
AFQ056
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Englewood, Colorado • Kansas City, Kansas • Milwaukee, Wisconsin
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Interventions
Dipraglurant
Drug
Lead sponsor
Addex Pharma S.A.
Industry
Eligibility
30 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Augusta, Georgia • Kansas City, Kansas • New Brunswick, New Jersey + 4 more
Conditions
Opioid Use, Opioid Dependence, Opioid-use Disorder, Narcotic Use, Back Pain, Back Injuries, Chronic Pain, Chronic Low-back Pain, Pain, Chronic, Pain;Back Low;Chronic, Pain, Back
Interventions
Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, Opioids
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Asthma
Interventions
CVT-301 (levodopa inhalation powder), Carbidopa, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Daytona Beach, Florida • North Dartmouth, Massachusetts • Dallas, Texas
Conditions
Parkinson Disease
Interventions
IV Levodopa, Talampanel
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Parkinson's Disease
Interventions
Accordion Pill™ Carbidopa/Levodopa
Drug
Lead sponsor
Intec Pharma Ltd.
Industry
Eligibility
30 Years to 100 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 33 more
Conditions
Parkinson's Disease
Interventions
Levodopa, Zolpidem first dose, Zolpidem second dose, sugar pill
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
30 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate, 1.0 mg rasagiline mesylate, Placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Rochester, New York + 1 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Sustained Release Oral Formulation for Treatment of Parkinson's Disease

NCT05471609
Conditions
Healthy Volunteers
Interventions
levodopa/carbidopa oral formulation A, levodopa/carbidopa oral formulation B
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Malignant Brain Neoplasm
Interventions
Computed Tomography, Fluorodopa F 18, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota